Next Article in Journal
Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy
Next Article in Special Issue
Dendritic Cell Regulation by Cannabinoid-Based Drugs
Previous Article in Journal
Overview of Histone Deacetylase Inhibitors in Haematological Malignancies
Previous Article in Special Issue
The Role of Cannabinoid Receptors in the Descending Modulation of Pain
Open AccessReview

Cannabinoids and Dementia: A Review of Clinical and Preclinical Data

University Hospital of Psychiatry, Bolligenstrasse 111, 3000 Bern 60, Switzerland;
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2010, 3(8), 2689-2708; https://doi.org/10.3390/ph3082689
Received: 23 June 2010 / Revised: 5 August 2010 / Accepted: 16 August 2010 / Published: 17 August 2010
(This article belongs to the Special Issue Cannabinoids)
The endocannabinoid system has been shown to be associated with neurodegenerative diseases and dementia. We review the preclinical and clinical data on cannabinoids and four neurodegenerative diseases: Alzheimer’s disease (AD), Huntington’s disease (HD), Parkinson’s disease (PD) and vascular dementia (VD). Numerous studies have demonstrated an involvement of the cannabinoid system in neurotransmission, neuropathology and neurobiology of dementias. In addition, several candidate compounds have demonstrated efficacy in vitro. However, some of the substances produced inconclusive results in vivo. Therefore, only few trials have aimed to replicate the effects seen in animal studies in patients. Indeed, the literature on cannabinoid administration in patients is scarce. While preclinical findings suggest causal treatment strategies involving cannabinoids, clinical trials have only assessed the suitability of cannabinoid receptor agonists, antagonists and cannabidiol for the symptomatic treatment of dementia. Further research is needed, including in vivo models of dementia and human studies. View Full-Text
Keywords: cannabinoids; Alzheimer’s disease; Huntington’s disease; Parkinson’s disease; vascular dementia cannabinoids; Alzheimer’s disease; Huntington’s disease; Parkinson’s disease; vascular dementia
MDPI and ACS Style

Walther, S.; Halpern, M. Cannabinoids and Dementia: A Review of Clinical and Preclinical Data. Pharmaceuticals 2010, 3, 2689-2708.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop